Home / Biotechnology / Circulating Tumor Cells Prognostic Technologies Market By Technology (Tumor Cells Enrichment, Tumor Cells Detection), By Application (Breast Cancer, Prostate Cancer, Colorectal Cancer, Others) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026

Circulating Tumor Cells Prognostic Technologies Market By Technology (Tumor Cells Enrichment, Tumor Cells Detection), By Application (Breast Cancer, Prostate Cancer, Colorectal Cancer, Others) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026

Published: Oct 2018 | Report Code: 59383-10-18

Industry Outlook

The circulating tumor cells prognostic technologies market is set to reach US$ 12,443.3 Mn by 2026 from US$ 2,324.7 Mn in 2017 projecting excellent growth at a compounded annual growth rate (CAGR) of 20.8% during the forecast period from 2018 to 2026. As per the latest research findings of World Health Organization (WHO) 2018, cancer is the second largest cause of death globally with an estimation of 9.6 million deaths in 2018. Worldwide approximately 1 in 6 deaths occur due to cancer with 70% of the deaths occurring in low and middle income countries.

Cancer is a universal terminology for a group of diseases that affect different parts of the human body, it is also known as neoplasm or malignant tumor. Cancer is the rapid creation of abnormal cells which grow from their site of origin also invades other organs through a process known as metastasis which is usually facilitated by circulating tumor cells. Metastasis is the major cause of death in cancer patients.

Market Synopsis

Circulating Tumor Cells Prognostic Technologies Market

Technological advancement in cell enrichment segment to drive the circulating tumor cells market

Currently the cell enrichment technology is dominating the circulating tumor cells prognostic technologies market. Recent technological advancement in cell enrichment techniques such as filtration, centrifugation and immunomagentic methods has resulted in improvised CTC’s functional characterization which finds prominence in disease diagnosis and target therapy. Other factor that drives the cell enrichment technology market is its increased adoption in biotechnology industries due to excellent accuracy and reliable methodology. Cell detection technology will foster impressive growth during the forecast period owing to the introduction of innovative and reproducible molecular biology technology such as isolation of CTC’s clusters from unprocessed blood. Standardization of optical methods in cell detection has resulted in conduction multicenter clinical trial studies.

Circulating Tumor Cells Prognostic Technologies Market

Rising incidence of breast cancer in women throughout the globe has resulted in positive traction for CTC’s prognostic technologies market

Breast cancer is the most common type of cancer in women worldwide with variegated prevalence rate ranging from 19.3 per 100,000 women in East Africa to 89.7% per 100,000 women in Western European region. In the developing nations breast cancer is diagnosed in late stages which results in low survival rate. Researchers throughout the globe are developing biomarkers such as CK3-11D5 and HER2 for effective diagnosis of non-metastatic breast cancer in women. Prostate cancer will exhibit impressive growth during the forecast period on account of factors such as old age and testosterone imbalance in men. The prevalence rate is high in developed regions such as Europe and North America as people consume diet rich in fat such as dairy products and red meat which stimulates the excessive production of testosterone leading to onset of prostate cancer. Epic Sciences, Inc., has developed AR-V7 liquid biopsy test for the accurate prognosis of patients suffering with metastatic prostate cancer.

Circulating Tumor Cells Prognostic Technologies Market

Increasing number of patients suffering with cancer and increased funding in R&D to develop CTC’s prognostic technologies drive the Asia Pacific market

North America currently holds the largest market in regional segment with 45% share. The key parameters responsible for its dominance are rising prevalence of cancer and increasing public health awareness resulting in early diagnosis. Domicile of key players such as AVIVA Biosciences and Epic Sciences, Inc., have catered to the prognostic needs of prostate and breast cancer in North America. According to World Health Organization (WHO) 2015 statistics, cancer is responsible for 20% of the deaths in Europe. Developed healthcare infrastructure and effective treatment guidelines for cancer propels the CTC’s prognostic technologies market in Europe. Asia Pacific serves as a lucrative market on account of factors such as increasing number of patients suffering with cancer and excellent research activities pertaining to development of biomarkers and antigens for cancer detection.

Circulating Tumor Cells Prognostic Technologies Market

Historical & Forecast Period

2016 – Historical Year

2017 – Base Year

2018-2026 – Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.

Circulating Tumor Cells Prognostic Technologies Market

Report Scope by Segments

Qualitative and quantitative market analysis were performed to determine the market estimation and compounded annual growth rate (CAGR). The market segment comprises of by technology, application and geography.

By Technology (2016–2026; US$ Mn)

  • Tumor Cells Enrichment
    • Centrifugation
    • Filtration
    • Immunological and Immunomagnetic Methods
  • Tumor Cells Detection
    • Molecular Methods
    • Optical Methods

By Application (2016–2026; US$ Mn)

  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Others (Pancreatic, Ovarian Cancer etc.)

Geography Segment (2016–2026; US$ Mn)

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • GCC
    • Rest of MEA

Market estimation and compounded annual growth rate (CAGR) for the report circulating tumor cells prognostic technologies was determined by applying the organic and inorganic market analysis. Technological innovations pertaining to the different types of CTC’s being applied for the prognosis of cancer is thoroughly discussed in the scope of the report. The key players spearheading the circulating tumor cells prognostic technologies market are Celula, Inc., Advanced Cell Diagnostics, Inc., Epic Sciences, Inc., AdnaGen GmbH, Fluxion Biosciences, Inc., AVIVA Biosciences Corporation, Rarecells USA, Inc., Vitatex, Inc., Silicon Biosystems S.p.A., and Veridex, LLC.

Key questions answered in this report

  • What is the market estimation and compounded annual growth rate (CAGR) for CTC’s prognostic technologies market?
  • Who are the key players actively engaged in developing CTC’s prognostic technologies?
  • What are the latest market trends and competition existing among key players of CTC’s prognostic technologies market?
  • Which is the leading and fastest growing technology segment in the CTC’s prognostic technologies market?
  • Which is the leading and fastest growing application segment in the CTC’s prognostic technologies market?
  • Which is the leading and fastest growing regional segment in the CTC’s prognostic technologies market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Circulating Tumor Cells Prognostic Technologies Market Portraiture
2.2. Global Circulating Tumor Cells Prognostic Technologies Market, by Technology, 2017 (US$ Mn)
2.3. Global Circulating Tumor Cells Prognostic Technologies Market, by Application, 2017 (US$ Mn)
2.4. Global Circulating Tumor Cells Prognostic Technologies Market, by Geography, 2017 (US$ Mn)

Chapter 3. Circulating Tumor Cells Prognostic Technologies Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Circulating Tumor Cells Prognostic Technologies Market, by Key Players, 2017

Chapter 4. Global Circulating Tumor Cells Prognostic Technologies Market, by Technology
4.1. Overview
4.2. Tumor Cells Enrichment
4.2.1. Centrifugation
4.2.2. Filtration
4.2.3. Immunological and Immunomagnetic Methods
4.3. Tumor Cells Detection
4.3.1. Molecular Methods
4.3.2. Optical Methods

Chapter 5. Global Circulating Tumor Cells Prognostic Technologies Market, by Application
5.1. Overview
5.2. Breast Cancer
5.3. Prostate Cancer
5.4. Colorectal Cancer
5.5. Others (Pancreatic, Ovarian Cancer etc.)

Chapter 6. Global Circulating Tumor Cells Prognostic Technologies Market, by Geography
6.1. Overview
6.2. North America Circulating Tumor Cells Prognostic Technologies Market Analysis, 2016 – 2026
6.2.1. North America Circulating Tumor Cells Prognostic Technologies Market, by Technology, 2016 – 2026 (US$ Mn)
6.2.2. North America Circulating Tumor Cells Prognostic Technologies Market, by Application, 2016 – 2026 (US$ Mn)
6.2.3. North America Circulating Tumor Cells Prognostic Technologies Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Circulating Tumor Cells Prognostic Technologies Market Analysis, 2016 – 2026
6.3.1. Europe Circulating Tumor Cells Prognostic Technologies Market, by Technology, 2016 – 2026 (US$ Mn)
6.3.2. Europe Circulating Tumor Cells Prognostic Technologies Market, by Application, 2016 – 2026 (US$ Mn)
6.3.3. Europe Circulating Tumor Cells Prognostic Technologies Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Circulating Tumor Cells Prognostic Technologies Market Analysis, 2016 – 2026
6.4.1. Asia Pacific Circulating Tumor Cells Prognostic Technologies Market, by Technology, 2016 – 2026 (US$ Mn)
6.4.2. Asia Pacific Circulating Tumor Cells Prognostic Technologies Market, by Application, 2016 – 2026 (US$ Mn)
6.4.3. Asia Pacific Circulating Tumor Cells Prognostic Technologies Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America Circulating Tumor Cells Prognostic Technologies Market Analysis, 2016 – 2026
6.5.1. Latin America Circulating Tumor Cells Prognostic Technologies Market, by Technology, 2016 – 2026 (US$ Mn)
6.5.2. Latin America Circulating Tumor Cells Prognostic Technologies Market, by Application, 2016 – 2026 (US$ Mn)
6.5.3. Latin America Circulating Tumor Cells Prognostic Technologies Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East and Africa Circulating Tumor Cells Prognostic Technologies Market Analysis, 2016 – 2026
6.6.1. MEA Circulating Tumor Cells Prognostic Technologies Market, by Technology, 2016 – 2026 (US$ Mn)
6.6.2. MEA Circulating Tumor Cells Prognostic Technologies Market, by Application, 2016 – 2026 (US$ Mn)
6.6.3. MEA Circulating Tumor Cells Prognostic Technologies Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. AdnaGen GmbH
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Technology Portfolio
7.1.4. News Coverage
7.2. Advanced Cell Diagnostics, Inc.
7.3. AVIVA Biosciences Corporation
7.4. Celula, Inc.
7.5. Epic Sciences, Inc.
7.6. Fluxion Biosciences, Inc.
7.7. Rarecells USA, Inc.
7.8. Vitatex, Inc.
7.9. Veridex, LLC.
7.10. Silicon Biosystems, S.p.A.

FIG. 1 Circulating Tumor Cells Prognostic Technologies Market: Research Methodology
FIG. 2 Circulating Tumor Cells Prognostic Technologies: Market Segmentation
FIG. 3 Global Circulating Tumor Cells Prognostic Technologies Market, by Technology, 2017 (US$ Mn)
FIG. 4 Global Circulating Tumor Cells Prognostic Technologies Market, by Application, 2017 (US$ Mn)
FIG. 5 Global Circulating Tumor Cells Prognostic Technologies Market, by Geography, 2017 (US$ Mn)
FIG. 6 Attractive Investment Proposition: by Geography, 2017
FIG. 7 Competitive Analysis: Global Circulating Tumor Cells Prognostic Technologies Market, by Key Players, 2017
FIG. 8 Global Centrifugation Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
FIG. 9 Global Filtration Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
FIG. 10 Global Immunological and Immunomagnetic Methods Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
FIG. 11 Global Molecular Methods Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
FIG. 12 Global Optical Methods Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
FIG. 13 Global Breast Cancer Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
FIG. 14 Global Prostate Cancer Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
FIG. 15 Global Colorectal Cancer Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
FIG. 16 Global Other Applications Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
FIG. 17 U.S. Circulating Tumor Cells Prognostic Technologies Market, 2016 – 2026 (US$ Mn)
FIG. 18 Canada Circulating Tumor Cells Prognostic Technologies Market, 2016 – 2026 (US$ Mn)
FIG. 19 U.K. Circulating Tumor Cells Prognostic Technologies Market, 2016 – 2026 (US$ Mn)
FIG. 20 Germany Circulating Tumor Cells Prognostic Technologies Market, 2016 – 2026 (US$ Mn)
FIG. 21 Rest of Europe Circulating Tumor Cells Prognostic Technologies Market, 2016 – 2026 (US$ Mn)
FIG. 22 China Circulating Tumor Cells Prognostic Technologies Market, 2016 – 2026 (US$ Mn)
FIG. 23 Japan Circulating Tumor Cells Prognostic Technologies Market, 2016 – 2026 (US$ Mn)
FIG. 24 Rest of Asia Pacific Circulating Tumor Cells Prognostic Technologies Market, 2016 – 2026 (US$ Mn)
FIG. 25 Brazil Circulating Tumor Cells Prognostic Technologies Market, 2016 – 2026 (US$ Mn)
FIG. 26 Mexico Circulating Tumor Cells Prognostic Technologies Market, 2016 – 2026 (US$ Mn)
FIG. 27 Rest of Latin America Circulating Tumor Cells Prognostic Technologies Market, 2016 – 2026 (US$ Mn)
FIG. 28 GCC Circulating Tumor Cells Prognostic Technologies Market, 2016 – 2026 (US$ Mn)
FIG. 29 Rest of MEA Circulating Tumor Cells Prognostic Technologies Market, 2016 – 2026 (US$ Mn)

TABLE 1 Global Circulating Tumor Cells Prognostic Technologies Market Portraiture
TABLE 2 Global Circulating Tumor Cells Prognostic Technologies Market, by Technology, 2016 – 2026 (US$ Mn)
TABLE 3 Global Tumor Cells Enrichment Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
TABLE 4 Global Tumor Cells Detection Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
TABLE 5 Global Circulating Tumor Cells Prognostic Technologies Market , by Application, 2016 – 2026 (US$ Mn)
TABLE 6 Global Circulating Tumor Cells Prognostic Technologies Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 7 North America Circulating Tumor Cells Prognostic Technologies Market, by Technology, 2016 – 2026 (US$ Mn)
TABLE 8 North America Circulating Tumor Cells Prognostic Technologies Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 9 North America Circulating Tumor Cells Prognostic Technologies Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 10 Europe Circulating Tumor Cells Prognostic Technologies Market, by Technology, 2016 – 2026 (US$ Mn)
TABLE 11 Europe Circulating Tumor Cells Prognostic Technologies Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 12 Europe Circulating Tumor Cells Prognostic Technologies Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 13 Asia Pacific Circulating Tumor Cells Prognostic Technologies Market, by Technology, 2016 – 2026 (US$ Mn)
TABLE 14 Asia Pacific Circulating Tumor Cells Prognostic Technologies Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 15 Asia Pacific Circulating Tumor Cells Prognostic Technologies Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 16 Latin America Circulating Tumor Cells Prognostic Technologies Market, by Technology, 2016 – 2026 (US$ Mn)
TABLE 17 Latin America Circulating Tumor Cells Prognostic Technologies Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 18 Latin America Circulating Tumor Cells Prognostic Technologies Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 19 Middle East and Africa Circulating Tumor Cells Prognostic Technologies Market, by Technology, 2016 – 2026 (US$ Mn)
TABLE 20 Middle East and Africa Circulating Tumor Cells Prognostic Technologies Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 21 Middle East and Africa Circulating Tumor Cells Prognostic Technologies Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 22 AdnaGen GmbH: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)
TABLE 23 Advanced Cell Diagnostics, Inc.: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)
TABLE 24 AVIVA Biosciences Corporation: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)
TABLE 25 Celula, Inc.: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)
TABLE 26 Epic Sciences, Inc.: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)
TABLE 27 Fluxion Biosciences, Inc.: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)
TABLE 28 Rarecells USA, Inc.: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)
TABLE 29 Vitatex, Inc.: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)
TABLE 30 Veridex, LLC: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)
TABLE 31 Silicon Biosystems, S.p.A.: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients